Principal Financial Group Inc Dyne Therapeutics, Inc. Transaction History

Principal Financial Group Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	SELL	$31.94 - $47.04 $200,391 - $295,128	-6,274 Reduced 45.56%	7,497 $269,000
Q2 2024 Jul 29, 2024	SELL	$23.65 - $35.63 $38,596 - $58,148	-1,632 Reduced 10.6%	13,771 $485,000
Q1 2024 Apr 29, 2024	BUY	$13.06 - $29.18 $11,192 - $25,007	857 Added 5.89%	15,403 $437,000
Q4 2023 Feb 07, 2024	SELL	$6.62 - $13.64 $4,521 - $9,316	-683 Reduced 4.48%	14,546 $193,000
Q3 2023 Nov 02, 2023	BUY	$8.6 - $12.18 $12,693 - $17,977	1,476 Added 10.73%	15,229 $136,000
Q2 2023 Aug 07, 2023	BUY	$8.53 - $14.28 $18,203 - $30,473	2,134 Added 18.37%	13,753 $154,000
Q1 2023 May 09, 2023	BUY	$10.88 - $15.0 $10,336 - $14,250	950 Added 8.9%	11,619 $133,000
Q4 2022 Feb 09, 2023	BUY	$9.37 - $13.8 $99,968 - $147,232	10,669 New	10,669 $123,000

209

102M

234K

238K

Ticker DYN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,765,400
Market Cap $1.24B
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.